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CA 90033, USARecent guidelines recommend that patients diagnosed with cir-
rhosis have endoscopy to screen for varices. Beta-blocker therapy
or endoscopic variceal ligation is recommended for those with
moderate-large varices that have not bled. This paper reviews
the evidence supporting the use of endoscopic ligation rather
than beta-blockers for primary prophylaxis in these patients.
Ligation is an effective treatment for the prevention of bleeding
among patients with esophageal varices that have never bled. Ameta-
analysis of 5 randomized trials with mean follow-up of 23months
revealed a signiﬁcant decrease in ﬁrst variceal bleeding (RR = 0.36,
95% CI, 0.26–0.50; number-needed-to-treat (NNT) = 4) and mortality
(RR = 0.55, 0.43–0.71; NNT = 5) as compared to no therapy [1].
Beta-blockers are also effective in decreasing ﬁrst variceal
bleeding (NNT = 11), with a trend to decreased mortality, com-
pared to placebo or inactive therapy in meta-analysis of 11 ran-
domized trials with median follow-up of 24 months [2].
Issues to consider in deciding whether to choose endoscopic
ligation or beta-blocker therapy include efﬁcacy, safety/tolerabil-
ity, patient preference, and cost/cost-effectiveness.Efﬁcacy
Meta-analyses consistently document a signiﬁcantly lower inci-
dence of ﬁrst upper gastrointestinal bleeding and variceal bleed-
ing with ligation vs. beta-blockers [3–5]. Relative risk reductions
are approximately 35% and NNTs approximately 14. The meta-
analyses, however, show no suggestion of a beneﬁt in mortality.
Subgroupanalyses (e.g., basedonsizeormethodologicqualityof
studies) have been performed as part of meta-analyses [5,6]. Point
estimates and widely overlapping conﬁdence intervals from these
analyses indicate that the treatmenteffectof ligationvs. beta-block-
ers is not signiﬁcantly different across the subgroups assessed.
Safety and tolerability
The incidence of severe adverse events or adverse events leading
to discontinuation of therapy is signiﬁcantly lower with ligationJournal of Hepatology 20
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Open access under CC BY-NC-ND license.than with beta-blockers, with relative risk reductions of approx-
imately 65–75% and NNTs of approximately 10 [3,4]. Critics of
ligation point out that although adverse events are less common
with ligation, rare side effects such as ligation-induced ulcer
bleeding can be much more severe than most beta-blocker
adverse events and are even rarely fatal. However, in almost all
published studies, if ligation-induced ulcer bleeding occurred it
was included in the primary bleeding endpoint. In addition,
meta-analyses show signiﬁcant beneﬁt when all bleeding epi-
sodes are considered—not just when variceal bleeding is consid-
ered [3]. Thus, even when ligation-induced ulcer bleeding is
included in the primary efﬁcacy endpoint, ligation is still signiﬁ-
cantly more effective than beta-blockers in a population of
patients with esophageal varices that have not previously bled.Patient preference
Incorporating patient preferences into clinical decision-making is
of great importance. A recent study assessed preferences of
patients and physicians [7]. Patients requiring primary prophy-
laxis of esophageal varices received a standardized educational
session on cirrhosis, varices, beta-blockers and ligation; and were
informed that both therapies were equally effective. Sixty-four
percent of the patients preferred ligation to beta-blocker therapy.
Shortness of breath and low blood pressure were the most impor-
tant factors to patients and physicians. Patients were much less
inﬂuenced by rare procedure-related complications than physi-
cians. Despite the patient preference for ligation, none received
ligation therapy.Cost and cost-effectiveness
Ligation therapy is more expensive than propranolol therapy
(especially in the ﬁrst year) although this cost difference should
be at least partially offset by the decrease in bleeding episodes
(and the cost of hospitalization for these episodes). Thus, we
must determine if the savings for preventing bleeding more than
offsets the additional costs of ligation therapy, and, if not, society
must decide if spending additional money to prevent a bleeding
episode is ‘‘cost-effective”.
A recent decision model, simulating standard clinical practice,
assessed primary prophylaxis in patients found to have moder-
ate-large varices at screening [8]. Ligation was more effective10 vol. 52 j 944–945
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and more expensive than beta-blockers, with an incremental cost
vs. beta-blocker therapy of $25,548 per quality-adjusted life-year
– well below the traditionally accepted ‘‘cost-effective” threshold
of $50,000–100,000.
Two small randomized trials assessed economic outcomes.
The ﬁrst found a non-signiﬁcantly higher estimated cost with
beta-blockers than ligation therapy ($3300 vs. $2228) in the US
[9], while the second study reported a signiﬁcantly lower cost
with beta-blockers ($1425 vs. $4289) in Italy [10].Combined therapy vs. single therapy
Two published randomized trials evaluated combination therapy.
One found no signiﬁcant beneﬁt of combination therapy (bleed-
ing: 7%; mortality: 8%) over ligation alone (bleeding: 11%; mor-
tality: 15%) [11], while the other reported that combination
therapy had signiﬁcantly lower rates of bleeding (8%) and mortal-
ity (11%) than propranolol alone (bleeding: 31%; mortality: 31%)
[12]. Thus, ligation improved the outcome of beta-blockers, but
beta-blockers did not improve the outcome of ligation. A recent
abstract, however, reported no difference between combination
therapy and beta-blockers alone [13].Conclusions
Ligation is an appropriate ﬁrst-line therapy for the prevention of
ﬁrst esophageal variceal hemorrhage in patients with moderate-
large varices. Ligation is more effective than beta-blocker therapy
in reducing ﬁrst bleeding, leads to fewer side effects and with-
drawals from therapy, and is preferred by a majority of patients.
Decision analysis also suggests that ligation is cost-effective as
compared to beta-blocker therapy.Conﬂicts of interest
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